A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
作者: Sapna P. PatelDae Won KimRoland L. BassettSuzanne CainEdwina WashingtonWen-Jen HwuKevin B. KimNicholas E. PapadopoulosJade HomsiPatrick HwuAgop Y. Bedikian
作者单位: 1The University of Texas MD Anderson Cancer Center
2Moffitt Cancer Center
3California Pacific Medical Center
4The University of Texas Banner MD Anderson Cancer Center
刊名: Cancer Immunology, Immunotherapy, 2017, Vol.66 (10), pp.1359-1366
来源数据库: Springer Journal
DOI: 10.1007/s00262-017-2030-y
关键词: IpilimumabTemozolomideMelanomaClinical trialRegulatory T cells
英文摘要: Checkpoint blockade has revolutionized the treatment of melanoma; however, it benefits only the minority of patients. Several agents have been combined with immunotherapy to improve T-cell activation and persistence including growth factor, chemotherapy, and radiation. Preclinical data suggest that temozolomide, which metabolizes to the same active compound as dacarbazine, selectively depletes regulatory T cells. This potential immunomodulatory effect of temozolomide provides rationale for combination with ipilimumab. We performed an open-label single-arm phase II study of ipilimumab plus temozolomide in the frontline setting for patients with metastatic melanoma and LDH ≤2× upper limit of normal. Ipilimumab was given at 10 mg/kg on day 1 and temozolomide 200 mg/m2 orally days...
原始语种摘要: Checkpoint blockade has revolutionized the treatment of melanoma; however, it benefits only the minority of patients. Several agents have been combined with immunotherapy to improve T-cell activation and persistence including growth factor, chemotherapy, and radiation. Preclinical data suggest that temozolomide, which metabolizes to the same active compound as dacarbazine, selectively depletes regulatory T cells. This potential immunomodulatory effect of temozolomide provides rationale for combination with ipilimumab. We performed an open-label single-arm phase II study of ipilimumab plus temozolomide in the frontline setting for patients with metastatic melanoma and LDH ≤2× upper limit of normal. Ipilimumab was given at 10 mg/kg on day 1 and temozolomide 200 mg/m2 orally days...
全文获取路径: Springer  (合作)
分享到:
来源刊物:
影响因子:3.637 (2012)

×
关键词翻译
关键词翻译
  • melanoma 黑瘤
  • metastatic 新陈代谢的
  • potentially 可能地
  • chemotherapy 化学疗法
  • antitumor 抗癌的
  • rationale 理论基础
  • study 学习
  • confirmed 已确认的
  • immunotherapy 免疫疗法
  • unexpected 突然的